Related Experiment Video
Updated: Sep 2, 2026

13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
[A monoclonal antibody reactive with scirrhous carcinoma of the stomach]
Abstract:
A monoclonal antibody reactive with human gastric carcinoma was established. When formalin-fixed, paraffin-embedded histological sections were stained by avidin-biotin-peroxidase complex method using this monoclonal antibody, it was found to react with 89% (17/19) of the scirrhous carcinomas (diffuse type of carcinoma) and 72% (13/18) of the differentiated adenocarcinomas of the stomach tested. However, this antibody did not react with normal gastric mucosa or various other normal tissues except the mucosa of the large intestine.
Related Concept Videos
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

